Sandbox vidit: Difference between revisions
Jump to navigation
Jump to search
Line 12: | Line 12: | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>Conversion</td><td> DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])</td></tr> | <tr><td>▸ '''''Conversion'''''</td><td> ▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''</td></tr> | ||
<tr><td>Rate control</td><td>[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class | <tr><td>▸ '''''Rate control'''''</td><td>▸ '''''[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''[[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''</td></tr> | ||
</table></div>|C02=<div style="float: left; text-align: left; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> Rate control therapy as shown in table below: | </table></div>|C02=<div style="float: left; text-align: left; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> Rate control therapy as shown in table below: | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>Rate control</td><td>[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class | <tr><td>▸ '''''Rate control'''''</td><td>▸ '''''[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''[[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''</td></tr> | ||
</table> <br><br> ''THEN'' <br><br> ❑ Attempt conversion as shown in table below: <br> | </table> <br><br> ''THEN'' <br><br> ❑ Attempt conversion as shown in table below: <br> | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>Conversion</td><td>Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br>DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])<br> Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) | <tr><td>▸ '''''Conversion'''''</td><td>▸ '''''Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])'''''<br> or <br>▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''<br> or <br>▸ '''''Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])'''''<br> or <br>▸ '''''Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' </td></tr> | ||
</table> </div> }} | </table> </div> }} | ||
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} | {{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} |
Revision as of 20:35, 11 March 2014
Therapeutic Approach
Shown below is an algorithm summarizing the therapeutic approach to atrial flutter.[1]
Atrial flutter | |||||||||||||||||||||||||||||||||||||||||||||||||
Unstable | Stable | ||||||||||||||||||||||||||||||||||||||||||||||||
❑ Look for the presence of any of these:
| ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours Rate control therapy as shown in table below:
THEN ❑ Attempt conversion as shown in table below:
| ||||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess need for therapy to prevent recurrence | |||||||||||||||||||||||||||||||||||||||||||||||||
❑ Administer antiarrythmic therapy to prevent recurrences as shown below:
| |||||||||||||||||||||||||||||||||||||||||||||||||
- ↑ "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.